Discover the Menstrual Cup

Healthy, Environmentally Friendly to Tampons or Disposable Pads

The Mooncup – known in the USA as MCUK – is the original silicone menstrual cup designed by women to be a convenient, safe and eco-friendly alternative to tampons and sanitary pads.

For too long, tampons and sanitary pads have monopolised the menstrual market -damaging the earth and our purses. But now, Mooncup is stepping up the fight for a more healthy, environmentally friendly and financially sensible alternative.

Sources

The Smart Ageing Health App

World’s First Interactive Mobile Clinic App on Elderly Care

Smart Ageing logo
World’s First Interactive Mobile Clinic App on Elderly Care

Smart Ageing app by BorderlessHealthLab is an interactive online/mobile learning application to help elderly people, their caregivers and family members in going through and managing the aging process in a smart way by focusing on a preventative approach, as it may come with a set of challenges that can seem overwhelming for some. With Smart Ageing app, you will be able to utilize a mobile platform to enable access to knowledge and information, ensuring that the elderly people and caregivers are sufficiently equipped and are confident to face challenges in elderly care. The app offers 11 modules that covers topics like “Successful Aging”, “Nutrition—Myths and Facts”, “Mental Wellness as You Age” and “Keeping Bones Strong”.

Sources

World Cancer Day 2014 Poster

Debunk the Cancer Myths

World Cancer Day 2014 poster
Promote the campaign for World Cancer Day by sharing posters with your friends and family

Debunk the Cancer Myths

  1. We don’t need to talk about cancer – PDF
  2. There are no signs or symptoms of cancer  – PDF
  3. There is nothing I can do about cancer  – PDF
  4. I don’t have the right to cancer care  – PDF

Resources – Like on Facebook

On Flickr®

Diethylstilboestrol: Pharmacology, Toxicology and Carcinogenicity in Experimental Animals

Some experimental evidence points to the possibility of a transgenerational carcinogenic effect after prenatal exposure to Diethylstilbestrol

Abstract

image of PubMed NCBI The Endocrine Society logo
Some experimental evidence points to the possibility of a transgenerational carcinogenic effect after prenatal exposure to Diethylstilbestrol.

Diethylstilboestrol (DES) exerts several toxic effects in experimental animals, by mechanisms which are still unclear. The genotoxicity of the drug has been attributed to a quinone metabolite and is mainly clastogenic, including sister chromatid exchange, unscheduled DNA synthesis, chromosomal aberrations, disruption of mitotic spindle and aneuploidy. There is evidence that genotoxic effects may occur also transplacentally. Intrauterine and early postnatal exposure to DES can cause a variety of dysplasias. In the offspring of female mice exposed to DES during pregnancy, histological changes are observed in the vaginal and cervical epithelium, the endometrium, the ovary, the testis and the epididymis. Prenatal exposure of rats to DES led to decreased litter size and to urethrovaginal cloaca, penile and testicular hypoplasia, and cryptorchidism. Vaginal ridging, vaginal adenosis, testicular hypoplasia and cryptorchidism have been observed in rhesus monkeys following prenatal exposure. There is sufficient evidence that diethylstilboestrol is carcinogenic in experimental animals, after either prenatal or postnatal exposure. Mice show a similar type of carcinogenicity to that observed in humans, target organs being vagina, cervix, uterus, ovary, mammary gland and testis. In rats, prenatal exposure to DES produces mostly mammary and pituitary tumours, but also some tumours of the vagina. Hamsters develop tumours of vagina, cervix, endometrium, epididymis, testis, liver and kidney. DES induces ovarian papillary carcinomas in dogs, and malignant uterine mesotheliomas in squirrel monkeys. Some experimental evidence points to the possibility of a transgenerational carcinogenic effect, since prenatal treatment of mice with DES is followed by an increased incidence of uterine and ovarian carcinomas in the second-generation descendants.
Experimental results could have been used to predict the adverse effects of DES observed in humans in the early 1970s: DES had been reported to be carcinogenic in mice in the 1930s, while experiments in the 1960s had provided evidence that exposure during pregnancy could result in an increased cancer risk in the progeny.

Sources:
  • Diethylstilboestrol: II, pharmacology, toxicology and carcinogenicity in experimental animals,
    NCBI, PMD: 1445734, Eur J Cancer. 1992;29A(1):149-55.
More DES DiEthylStilbestrol Resources

David Healy misrepresents All Trials and Ben Goldacre

This blog post by David Healy is absurd – Dr Ben Goldacre response to Dr David Healy

After I posted “Fu*£ed or WTF is going on? @DrDavidHealy Thoughts about #AllTrials @BenGoldacre #GSK @Truthman30” yesterday, Dr Ben Goldacre visited DES Daughter Network’s blog leaving a comment which has now appeared on Dr David Healy’s website. I only added few related links (in the original text response) with the purpose to bring more clarity and/or references to the readers.

image of ben goldacre
Ben Goldacre is doctor, nerd cheerleader, Bad Science person, stats geek, procrastinator.

” Hi there,

I’ve posted this on David Healy’s blog, it’s currently “In Moderation” so I’m posting it here too in case it’s of interest.

This blog post by David Healy is absurd.

The AllTrials campaign is really simple: it calls for all trials to be registered, with their full methods and results made publicly available. Where CSRs have been made, we call for those to be placed in the public domain.

Healy says we’ve created a situation where people are withholding CSRs: that’s simply absurd, this is precisely what we campaign against.

Healy says we’ve created a situation where CSRs are inappropriately redacted: that’s absurd, again, this is specifically what we campaign against.

Healy says we have created a situation where drug companies get to choose who has access to CSRs: again, that is ridiculous, this is exactly what we campaign against.

GSK have signed up to the AllTrials campaign: they join over a hundred patient groups, more than 75,000 members of the public, NICE, Wellcome, MRC, almost all academic and medical professional bodies in the UK, and a growing number around the world. When Bad Pharma came out, industry and others were able to pretend that information about clinical trials is no longer withheld. We’ve transformed that, triggered two select committees and put the policy issue on the map, created a coalition, unpicked a web of dangerous false reassurances by professional bodies, and made it impossible for industry to engage in glib denialism.

I’m delighted that GSK have signed up to AllTrials, along with all the other organisations. There are lots of problems in medicine. There lots of people and organisations who’ve done – and continue to do – things I think are harmful to public health. But where people do the right thing, I will applaud them for it. I genuinely think that’s the right thing to do. It doesn’t mean you’re part of an elaborate and complex conspiracy with people. It doesn’t mean you approve of everything they do at work and at home.

It’s easy, and attractive, to scream from the sidelines, and carry on screaming forever. It’s also possible to shout out clearly and succinctly about problems, try to set out and discuss clear solutions, floodlight the path forwards, and encourage people to go down it.

Lastly, and specifically, the issue of individual personal data. The AllTrials campaign doesn’t call for all the rich individual patient data from all trials to be simply posted publicly in the public domain: that poses too much of a privacy risk, because patients are identifiable in this data. This privacy risk isn’t as big as is claimed by some of those who seek to block transparency, but we decided that the issues around graded access control to IPD are too complex for a simple headline campaign, and we didn’t want to risk industry using the issues around protecting participants’ privacy as an excuse to derail discussion on the very important separate issue of access to methods and summary results. We were absolutely right: industry have repeatedly tried to pretend that AllTrials calls for individual trial participants’ personal data to be posted online, even though AllTrials is specifically focused on registration, methods, results, and CSRs. But as David Healy knows, most of the people involved in the AllTrials campaign, myself, Iain Chalmers and the BMJ included, are closely involved in pushing for greater transparency on IPD too. It is simply absurd to claim otherwise.

The comments section on this blog is clearly the worst place to say this, but it really is a big waste of everyone’s time to have to deal with the kind of misrepresentation and abuse that David Healy keeps posting. From past experience, I don’t believe that David will engage constructively with my taking the time to correct these repeated misrepresentations, and I honestly think that’s a shame. We’re all – most of us at any rate – trying to get things improved. Everyone’s time is short, and people run things like AllTrials in their spare time. If Healy has a better way to make things better, that’s great, he should crack on with it and get others behind him. If it involves misrepresenting campaigns, smearing people, shouting abuse, and hectoring from the sidelines, then I won’t be in.

As an addendum, three brief specifics, since time is short:

David Healy, above: 
“Consent processes in clinical trials were about telling you you were on a new drug that might be dangerous or might be involved in a marketing trial. Instead they have become a way for companies to justify hiding your data on the basis of a confidentiality clause they have slipped into the forms. Iain ChalmersBen Goldacre and AllTrials appear to have signed up to this.”
– This is complete and utter fantasy. Neither I nor AllTrials have signed up to this. David Healy will be unable to provide any evidence to show that we have. Consent forms being used to justify withholding information is exactly what I’ve campaigned against.

David Healy, above:
 “That what would be put in place was a mechanism that gave the appearances of transparency but in fact would lock academics into agreeing with GSK and other companies as to what the outcomes of their trials have been.”
– This is completely bizarre. AllTrials simply calls for all trials to be registered, with their full methods and results made freely publicly available, and CSRs where they’ve been created. It is impossible to argue that this “locks academics into agreeing with GSK and other companies as to what the outcomes of their trials have been”.

David Healy, above:
 “Rape is a loaded word these days”.
It’s always been a loaded word, David. “

The Affordable Care Act infographic

Read Key Features of the Affordable Care Act on WomensHealth.gov

The Affordable Care Act Infographic
Visit WomensHealth.gov

The Affordable Care Act

Read Key Features of the Affordable Care Act
Read Speaking to Women’s Unique Health Needs
Read the Law and download the Full Text

Get more information

Visit WomensHealth.gov.
Get the National Women’s Health Week Social media toolkit.
Join or plan a Meetup.
Our posts tagged infographics.

On Flickr®

Fu*£ed or WTF is going on?

Dr. David Healy: “We told you here 18 months ago not to trust GSK – but BMJ and All Trials went ahead”…

image of David Healy
David Healy is professor of psychiatry and co-founder of data based medicine, operating through RxISK.org , working towards making medicines safer.

Last year, after GlaxoSmithKline (GSK) was fined $3 billions, then signed the All Trials campaign, we were wondering if other pharmaceutical companies would follow GSK plans to share detailed clinical trial data online for researchers. What if “their selective transparency is a smokescreen for a wider, more nefarious agenda, which is further control” warns @Truthman30…

In his recent post, Dr. David Healy explains the following:

Read Fucked – Apologies for the Language
by Dr David Healy, CEO of RxISK, May 21, 2014.

The Medically Informed Minder App

Designed to support domestic helpers, caregivers, and minders in providing quality home care for elderly individuals

The Medically Informed Minder app by BorderlessHealthLab is designed to support domestic helpers, caregivers, and minders in providing quality home care for elderly individuals. Special emphasis is placed on helping caregivers and minders navigate through complex bio-psycho-social scenarios in elderly care, in a simple Learn – Observe – Recall – Practice methodology.
The MIM Viewer app is also on Facebook.

Sources

Calorie Restriction during Treatment for Breast Cancer proving Better Outcomes

Fighting cancer with dietary changes

Logo of Science Daily
There is a range of research to demonstrate that calorie restriction augments the effectiveness of #cancer treatments.

Calorie restriction during treatment for breast cancer changes cellular programming in a way that lowers the chance of metastases in mice. Breast cancer patients are often treated with hormonal therapy to block tumor growth, and steroids to counteract the side effects of chemotherapy. However, both treatments can cause a patient to have altered metabolism which can lead to weight gain. In fact, women gain an average of 10 pounds in their first year of treatment. Recent studies have shown that too much weight makes standard treatments for breast cancer less effective, and those who gain weight during treatment have worse cancer outcomes.

Women 18 years of age or older who have been diagnosed with early stage breast cancer and will undergo radiation therapy for treatment may be eligible to participate in the CaReFOR (Calorie Restriction for Oncology Research) trial. If you are interested in learning more about participating in this study, please contact Thomas Jefferson University Hospitals team at carefortrial@gmail.com and/or Edyta Zielinska, edyta.zielinska@jefferson.edu, 215-955-5291.

Sources and Related Studies
  • Fighting cancer with dietary changes,
    ScienceDaily, 2014/05/140526101503, May 26, 2014.
  • The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster,
    Springer, article/10.1007%2Fs10549-014-2978-7, May 2014.
  • Counting Calories to Curb Breast Cancer,
    Jefferson, blog, March 11th, 2014.
  • Caloric restriction augments radiation efficacy in breast cancerJeffersonCell Cycle 12:12, 1955–1963, June 15, 2013.
  • Jefferson Opens Calorie Restriction Trial for Early Stage Breast Cancer Patients on Radiation Therapy,
    KimmelCancerCenter, p=3686, February 12th, 2013.

Worse than the Disease: Pitfalls of Medical Progress

DES and the Elusive Goal of Drug Safety

Worse than the Disease - Pitfalls of Medical Progress book cover
Includes “DES and the elusive goal of drug safety” case study

Synopsis:
The distance between medical and public priorities is exposed in four case studies that reveal the human choices governing scientific innnovation and explore the political, economic and social factors influencing those choices.

Description
This book – by Diana Barbara Dutton – examines four medical innovations that epitomize the pitfalls of progress:

  • DES and the elusive goal of drug safety – about a synthetic estrogen prescribed to millions of women to supposedly prevent miscarriages, which produced devastating side effects;
  • the artificial heart;
  • the 1976 swine flu immunization programme;
  • genetic engineering: science and social responsibility.

Dutton and the contributors trace the human choices that govern medical and scientific innovation and explore the political, economic, and social factors that influence those choices. In the process, they reveal a deep gulf between the priorities of medical innovation and the concerns of the general public. They then propose concrete policy changes to help bridge that gulf.

More DES DiEthylStilbestrol Resources